In vitro anticancer screening of Tibetan medicines

Sijian ZHENG,Chan XU,Jie YANG,Yun HUANG,Yanzhang WEN,Ping SONG,Qinxiong LIN,Qiang WANG,Xinzhou YANG

DOI: https://doi.org/10.3969/j.issn.1000-1190.2017.03.011

2017-01-01

Abstract:The extraction of cyclohexane,ethyl acetate and methanol from 100 commonly used Tibetan medicines was prepared by the accelerated solvent extraction method.The MTT method was used to test antitumor activity of these 100 tibetan medicines against two hepatocellular carcinoma cell lines HepG2 and SMMC-7721,while preliminary toxicity towards normal human cells was investigated using a human liver cell line L-02.The antitumor screening results showed that 17 tibetan medicines exhibited antitumor activities against HepG2 and SMMC-7721 with IC50 values less than 150 μg/mL.Among them,the ethyl acetate extracts of Aristolochia impresinervis,Delphinium caeruleum,Dracocephalum tanguticum and Ligularia przewalskii showed significant antitumor activity against HepG2 and SMMC-7721 with IC50 values less than 50 μg/mL,but tthat of Aristolochia impresinervis showed certain toxicity against L-02 up to 200 μg/mL.In the further validation of anti-HepG2 liver cancer activity,the results signified that the ethyl acetate extracts of Delphinium caeruleum and Dracocephalum tanguticum had significant anti-hepatocarcinoma activities,both of which presented significant time and dose dependent relationships against HepG2 hepatocarcinoma cell lines.The morphological changes of HepG2 cells treated with the ethyl acetate extracts of Delphinium caeruleum or Dracocephalum tanguticum were investigated by inverted microscope and Hoechst 33258 fluorescent staining method.The results demonstrated that apoptosis were induced by the ethyl acetate extracts of Delphinium caeruleum and Dracocephalum tanguticum anti-cancer in HepG2 cells.